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Background and aims: Nucleotides form the building blocks of DNA and are marketed as dietary
supplements, alone or in combination with other ingredients, to promote general health. However, there
has been only limited scientific study regarding the true biological activity of orally administered
nucleotides. We therefore tested their efficacy in a variety of models of epithelial injury and repair.
Methods: Effects on proliferation ([3H] thymidine incorporation) and restitution (cell migration of wounded
monolayers) were analysed using HT29 and IEC6 cells. The ability of a nucleotide mixture to influence
gastric injury when administered orally and subcutaneously was analysed using a rat indomethacin
(20 mg/kg) restraint model.
Results: In both cell lines, cell migration was increased by approximately twofold when added at 1 mg/ml
(p,0.01); synergistic responses were seen when a mixture of nucleotides was used. Cell proliferation was
stimulated by adenosine monophosphate (AMP) in HT29, but not in IEC6, cells. Gastric injury was reduced by
approximately 60% when gavaged at 4–16 mg/ml (p,0.05), concentrations similar to those likely to be found
in consumers taking nucleotide supplements. Systemic administration of nucleotides was unhelpful.
Conclusions: Nucleotides possess biological activity when analysed in a variety of models of injury and
repair and could provide a novel inexpensive approach for the prevention and treatment of the injurious
effects of non steroidal anti-inflammatory drugs and other ulcerative conditions of the bowel. Further
studies on their potential benefits (and risks) appear justified.
N
atural medicinal products have been used for millen-
nia for the treatment of multiple ailments. Although
many have been superseded by conventional pharma-
ceutical approaches, there is currently a resurgence of interest
in the use of natural bioactive products by the general public,
with many healthy subjects and patients taking them for the
prevention and treatment of multiple conditions, including
gastrointestinal disorders and postoperative recovery.1
Unfortunately, current evidence of the scientific validity of
many of these traditional and commercial compounds is
severely limited.
Nucleosides and nucleotides (NTs) serve as building blocks
for RNA and DNA synthesis for cells. Cell turnover is very
rapid in the gut and requires considerable amounts of NTs.
The intestine can synthesise NTs from amino acids and other
precursors but de novo NTs synthesis may be limited and the
gut may also be dependent on exogenous supplies of NTs.2
Therefore, a dietary source of NTs may optimise the function
of rapidly dividing cells, such as those of the gastrointestinal
tract, especially during periods of starvation or stress.
NTs are currently sold in pure individual form (particularly
adenosine based), as NT mixtures, or as part of multiple
ingredients in dietary supplements in health food shops.
Multiple claims for these products have been made, including
improving gastrointestinal and liver health, strengthening
the immune system, promoting tissue renewal and wound
healing, and benefiting athletic performance. The strength of
the data supporting these claims are however limited.
We have therefore performed a series of studies to analyse
the effects of NTs, given individually and in combination,
with regard to mechanisms of gut integrity and repair using
well validated in vitro and in vivo models.
MATERIALS AND METHODS
All chemicals were purchased from Sigma (Poole, Dorset)
unless otherwise stated.
Ethics
All animal experiments were approved by the Imperial
College School of Medicine Animals Ethics Committee and
covered by the appropriate licences under the Home Office
Animals Procedures Acts, 1986.
Study series A: effect of nucleotides on in vitro models
of repair
Background to methods
One of the earliest biological repair responses following injury
to tissue cells is migration of surviving cells over the denuded
area caused by the injury to re-establish epithelial integrity.
As it is extremely difficult to study this effect on organ tissue
inside a human or animal, cell culture models are commonly
used as surrogate markers of this promigratory response.
Approximately 24 hours after the injury has occurred, there is
also an increase in the rate of cell division in order to re-
establish a normal mucosa. Cell culture models have
traditionally also been used as surrogate markers for this
proliferation response, and because thymidine is a natural
constituent of DNA,[3H]thymidine incorporation is com-
monly used as a marker of proliferation. Cells that are
actively dividing will therefore increase their uptake of
thymidine in the preparatory state of cell division.
Cell migration as a model of wound repair
Cell migration assays were performed using our previously
published methods.3 Briefly, human colonic carcinoma (HT29)
and rat intestinal epithelial (IEC6) cells were grown to
confluence in six well plates in medium consisting of
Abbreviations: AMP, adenosine monophosphate; CMP, cytidine
monophosphate; GMP, guanosine monophosphate; IMP, inosine
monophosphate; DMEM, Dulbecco’s modified Eagle’s medium; EGF,
epidermal growth factor; NSAID, non-steroidal anti-inflammatory drugs;
NT, nucleotides
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Dulbecco’s modified Eagle’s medium (DMEM) containing 10%
fetal calf serum at 37˚ C in 5% CO2. The monolayers were then
wounded by scraping a disposable pipette tip across the dishes,
washed twice with fresh serum free medium, and cultured in
serum free medium in the presence of individual NTs
(adenosine monophosphate (AMP), cytidine monophosphate
(CMP), guanosine monophosphate (GMP), inosine monophos-
phate (IMP)) alone or in combination. Additional monolayers
containing a mixture of equal amounts of each NT, at a total
final concentration of 1 mg/ml, also had the proliferation
inhibitor, mitomycin C, added at 5 mg/ml in order to examine
whether wound closure was dependant on cell proliferation.
The rate of movement of the anterior edges of the wounded
monolayers was then determined by taking serial photomicro-
graphs at various times after wounding.3 An inverted micro-
scope (Nikon TS100) and a Nikon Coolpix 800 digital camera
with 125-fold magnification were used to obtain photomicro-
graphs. Identical regions were examined at each time point by
pre-marking the base of the plates to facilitate alignment.
Twenty measurements per field were performed by placing a
transparent grid over the photograph and measuring the
distance moved from the original wound line. All results are
expressed as the mean (SEM) of three separate experiments.
Cell proliferation
Cell proliferation assays were performed using our previously
published methods.4 Briefly, IEC6 cells and HT29 cells were
grown in DMEM containing glutamine and 10% fetal calf
serum. Effects of NT and epidermal growth factor (EGF,
positive control) were subsequently tested under serum
starved conditions. To assess the rate of cells entering DNA
synthesis,[3H]thymidine (2 mCi/well) was included 24 hours
after addition of the test factors and cells were left for a
further 24 hours. For each condition, the stimulatory or
inhibitory effect of the solutions was measured in quadruplet
in six separate wells.
Study B: effect of the nucleotide mixture on an in vivo
rat gastric damaging model
Background to method
Although cell culture studies provide valuable information
regarding potential bioactivity, additional information may
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Figure 1 Effect of nucleotides (NTs) on wound healing, as assessed by cell migration. Standard wounds were inflicted on monolayers of (A) the human
colonic cell line HT29 or (B) rat intestinal epithelial IEC6 cells. The degree of movement at various time points after wounding was then assessed in the
presence or absence of various test factors. Addition of various concentrations of an NT mixture (0.1, 0.5, 0.75, and 1 mg/ml) stimulated a dose
dependant increase in the rate of migration of the cells. Maximal stimulation was seen at 1 mg/ml for both cell lines. A negative control (Dulbecco’s
modified Eagle’s medium (DMEM) alone) and a positive control (epidermal growth factor (EGF) 10 mg/ml) were also tested. p,0.01 versus control for
all times after four hours for all doses of NTs in both cell lines. (C, D) Results of the distanced travelled at a single time point (24 hours) after injury. (C)
Addition of the single NTs adenosine monophosphate (AMP), cytidine monophosphate (CMP), or inosine monophosphate (IMP) (1 mg/ml) stimulated
increased movement in HT29 cells compared with the negative control (DMEM alone). Guanosine monophosphate (GMP) had no significant effect. The
most pronounced promigratory effect was seen when an equal mixture of NTs was used at a total final total concentration of 1 mg/ml. EGF (10 mg/ml)
was used as a positive control. (D) Addition of the single NTs AMP, GMP, CMP, and IMP(1mg/ml) had no significant effect on stimulated restitution in
IEC6 cells compared with the negative control (DMEM alone). In contrast, addition of a mixture of NTs, also at a total final concentration of 1 mg/ml,
markedly stimulated the rate of migration. EGF (10 mg/ml) was used as a positive control. **p,0.01 versus negative control.
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also be gained by extending studies to the in vivo situation.
The ability of NTs to prevent gastric damage in rats stressed
by indomethacin and restraint was therefore also assessed
using a well validated model.3 5
Method
Male Sprague Dawley rats (225–275 g; Harlan Olac Ltd, UK)
were housed in standard cages (four animals per cage) and
fed standard laboratory chow (Special Diet Services, Essex,
UK) and tap water ad libitum.
Rats were randomised to receive, by gastric gavage, one of
the following: 1 ml of saline alone or varying concentrations
of the NT mixture (1–16 mg/ml) in saline. Additional animals
received intragastric EGF at a concentration of 25 mg/ml
(positive control). As in previous studies using this model, all
gastric solutions also contained 2% hydroxypropylmethyl-
cellulose to reduce the rate of gastric emptying.
Thirty minutes after gavage, all animals were placed in
Bollman-type restraint cages and received indomethacin
(20 mg/kg subcutaneously). Three hours later, animals were
killed by stunning and cervical dislocation. The stomachs
were then removed, the pH of the gastric contents measured,
the stomachs inflated with 4 ml of 10% formalin, and stored
overnight in 10% formalin. Stomachs were subsequently
randomly coded and macroscopic and microscopic assess-
ments of injury assessed in a blinded fashion. Macroscopic
injury was assessed using a dissecting microscope (610)
with the aid of a reference square grid and reported as the
total area of ulceration per stomach (mm2/stomach). The
stomachs were then embedded in wax and the depth of
damage assessed microscopically as previously described.5
Briefly, microscopic injury was graded with a score from 0 to
4 where 0 = no damage, 1 = one small erosion (less than
0.5 mm), 2 = two small or one large erosion (.0.5 mm),
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Figure 2 Effect of nucleotides (NTs) on
proliferation of human colonic
carcinoma HT-29 cells. (A) Addition of
the mixture of NTs stimulated
proliferation in a dose dependent
manner (1–10 mg/ml) compared with
the negative control (Dulbecco’s
modified Eagle’s medium (DMEM)
alone). Concentrations higher
than10 mg/ml had no effect on, or
reduced the amount of, proliferation.
(B) Studies of individual NTs showed
that adenosine monophosphate (AMP)
stimulated proliferation in a dose
dependent manner compared with the
negative control (DMEM alone).
Addition of cytidine monophosphate
(CMP) (C), guanosine monophosphate
(GMP) (D), and inosine monophosphate
(IMP) (E) had no effect or reduced the
level of thymidine uptake compared
with the negative control. Epidermal
growth factor (EGF 10 mg/ml) was
used as a positive control. **p,0.01
versus negative control.
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3 = two or more large erosions, and 4 = any area of ulceration
extending to the muscularis mucosa.
In addition, in order to examine the importance of the
route of administration on any effects seen, an additional
series of rats were treated in a similar way but received test
substances (saline or 2, 4, or 8 mg/kg/h of the NT mixture)
via a continuous subcutaneous infusion rather than via
gavage. Additional animals received subcutaneous infusions
of EGF at a concentration of 5 mg/kg/h (positive control).
Statistics
All values are expressed as mean (SEM). One or two way
ANOVA was used as appropriate. Where a significant effect
was seen (p,0.05), individual comparisons were performed
using t tests based on group means, residual, and degrees of
freedom obtained from the ANOVA, a method equivalent to
repeated measures analyses.
RESULTS
Cell migration as a model of wound repair
Addition of the NT mixture to either HT29 or IEC6 cells
resulted in a significant (p,0.05) dose dependant increase in
cell migration (fig 1A, B). Maximal stimulation was seen at
1 mg/ml; higher doses did not enhance migration further
(data not shown).
Cells which had been incubated with the NT mixture and
the proliferation inhibitor mitomycin C showed a similar
promigratory activity to that seen in wells incubated with the
NT mixture alone, confirming that the restitutive effects seen
were not dependant on cell proliferation (data not shown).
When HT29 cells were used, addition of AMP, CMP, or IMP
alone, at 1 mg/ml, resulted in an increase in the rate of cell
migration. In contrast, GMP given alone (1 mg/ml) was
ineffective. However, addition of the mixture of all four NTs
together (at a final total concentration of 1 mg/ml) resulted
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Figure 3 Effect of nucleotides (NTs) on
proliferation of rat intestinal IEC6 cells.
Addition of the mixture (A) or single
NTs (10–2500 mg/ml) (B–E) did not
stimulate proliferation compared with
the negative control (Dulbecco’s
modified Eagle’s medium (DMEM)
alone). Epidermal growth factor (EGF
10 mg/ml) was used as a positive
control. AMP, adenosine mono-
phosphate; CMP, cytidine monophos-
phate; GMP, guanosine monophosphate;
IMP, inosine monophosphate. **p,0.01
versus control.
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in a much greater promigratory response than any of the
individuals NTs given alone (fig 1C).
When IEC6 cells were used, addition of any of the single
NTs alone, at 1 mg/ml, did not increase the rate of cell
migration whereas a strong response was seen with the
mixture (fig 1D).
Cell proliferation
In HT29 cells, addition of the mixture of NTs at 1–10 mg/ml
resulted in a significant increase in thymidine incorporation.
However, this effect was lost if the mixture was added at
concentrations above 10 mg/ml (fig 2A).
Analyses of the effect of adding individual NTs to HT29
cells showed that the proproliferative effect was probably
mainly due to the AMP constituent as AMP administered
alone at 5–100 mg/ml also resulted in a dose dependant
increase in proliferation (fig 2B). None of the other NTs
administered alone increased proliferation in HT29 cells
(fig 2C–E).
In contrast with the results seen in HT29 cells, when IEC6
cells were used, addition of the NTs, given alone or as a
mixture, did not increase thymidine uptake above baseline
(fig 3).
Effect of the nucleotide mixture on an in vivo rat
gastric damaging model
Oral administration of the NT mixture significantly reduced
the degree of macroscopic indomethacin/restraint induced
gastric damage (fig 4A). Similar results were found when the
same tissue was analysed by microscopic scoring (data not
shown).
In contrast with the findings of giving NT by gavage,
subcutaneous administration of the NT mixture did not
reduce the amount of indomethacin/restraint induced macro-
scopic gastric damage at any of the doses used (fig 4B) and,
at the two higher doses tested (4 and 8 mg/kg/h), the amount
of macroscopic damage induced was significantly increased.
Assessment of the same tissues using the microscopic scoring
system gave similar results (data not shown).
In both oral and subcutaneous treated animals, median
intragastric pH values for animals receiving control and test
factor infusions were similar, at about pH 2.2 (range 1.8–2.6).
DISCUSSION
We have shown that NTs, which are currently commercially
available in health food stores in either pure or mixed forms,
induce promigratory activity. They may also possess propro-
liferative activity, dependant on the cells being tested. In
addition, we showed that a NT mixture was able to reduce
the degree of injury sustained in an in vivo rat gastric
damaging model.
For the in vitro studies, rat small intestinal (IEC6) and
human colonic (HT29) cells were used to the examine the
effects on cells from different species and regions of the
bowel. We found that AMP, CMP, and IMP given alone
stimulated migration of human HT29 cells whereas GMP did
not. In addition, we found additive/synergistic effects when
the mixture of NTs was given together. These results extend
the previous observation by Dignass et al that addition of ATP
or ADP stimulates restitution of IEC6 cells.6 This group did
not assess the other NTs and in contrast with our findings
they did not find a promigratory effect using AMP. The
reasons for this difference in AMP results in IEC6 cells is
unclear.
In IEC6 cells, no effect on proliferation was seen when
CMP, GMP, or IMP was added, whereas AMP or the NT
mixture tended to reduce the degree of proliferation. Our
results are generally in keeping with the findings of Dignass
et al who reported antiproliferative effects of ATP and ADP
when added to IEC6 cells.6 Interestingly, a different set of
results were seen in our studies when we also examined
HT29 cells. In these cells, a proproliferative effect was seen
when AMP or the NT mixture was used. These results
confirm the need for caution in extrapolating results from in
vitro studies, usually using cancer cell lines, to the in vivo
situation. The effects of NTs on proliferation do however
appear to vary with the cells under study as placental derived
polydeoxyribonucleotides have been reported to increase
proliferation of primary skin fibroblasts.7 A potential expla-
nation for these differences in results may be the presence or
absence of relevant NT receptors on the cells under study.
Nucleotides act on at least two families of receptors: the
ionotropic P2X receptors and the G protein coupled P2Y
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Figure 4 Effect of nucleotide (NT) administration on the amount of
indomethacin induced gastric damage. (A) Rats (n = 9–16) were given
an oral gavage (1 ml) of saline (negative control), epidermal growth
factor (EGF 25 mg/ml, positive control), or the NT mixture (4, 8, or
16 mg/ml). All solutions also contained 2% hydroxypropylmethyl-
cellulose to delay gastric emptying. Thirty minutes later they were placed
in restraint cages, given indomethacin 20 mg/kg (subcutaneously), and
left in the cages for a further three hours. At the end of the study, animals
were killed and the amount of macroscopic and microscopic (data not
shown) damage (per mm2/stomach) determined. *p,0.05, ** p,0.01
versus saline control. (B) To examine the importance of the route of
administration, additional rats were placed in restraint cages and a
continuous subcutaneous infusion of saline (negative control) or NT
mixture (2–8 mg/kg/h in saline) started. EGF (5 mg/kg/h) in saline was
used as a positive control. Thirty minutes later all animals also received
indomethacin 20 mg/kg (subcutaneously) and were left for a further
three hours. At the end of the study, animals were killed and the amount
of macroscopic and microscopic (data not shown) damage (per mm2/
stomach) determined. **p,0.01, less damage versus control; p,0.05,
p,0.01, more damage versus control.
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receptors. Whereas P2X receptors are predominantly recep-
tors of ATP, the different P2Y receptors are activated by
distinct NTs, diphosphates or triphosphates, or purines or
pyrimidines, some of them being conjugated to sugars. The
finding that the effects on proliferation and migration were
dissociated in the two cell lines (that is, promigration was
seen in both cell lines whereas different effects were seen on
proliferation) suggests that the receptors involved in the two
processes are likely to be different. Additional experiments,
including detailed pharmacological analogue studies, are
required to unravel this further. For detailed review of NT
receptors see Murugappan and colleagues.8
Studies examining the potential beneficial effect of the NT
mixture on gastric injury were performed using indometha-
cin induced injury in rats as we have previously validated this
model for other bioactive agents such as bovine colostrum,4
and non-steroidal anti-inflammatory drugs (NSAIDs), such
as indomethacin, continue to be a major cause of morbidity
and mortality in humans.9 As is the situation with cell culture
studies, caution always has to be shown in extrapolating
results obtained from animal models to the human situation.
Results from the restitution studies suggested that additive
synergistic effects were present if a mixture of NTs were used.
In addition, most nutritional supplements tend to use
mixtures of NTs rather than a single one. We therefore
decided to examine the effects of a mixture of NTs in our in
vivo study. We found that oral administration of the NT
mixture was capable of reducing gastric injury by approxi-
mately 60% whereas systemic administration was unhelpful
and actually increased the degree of injury. Taken together,
these results suggest that the protective actions of oral NTs
were mediated via local mechanisms. Importantly, the
concentrations used in our restitution studies (1 mg/ml),
and in our gastric damage model (4–16 mg/ml), are likely to
be present in the human gastric juice of subjects taking NT
supplements, as the NT components within these products
usually comprise 1–100 mg/capsule, dependant on the source
and individual product.
The mechanism(s) by which oral administration of NTs
decreased gastric injury is unclear. This effect did not appear
to be mediated through alteration in gastric acid and
therefore NTs can be considered as cytoprotective agents.
Indomethacin causes damage to the gastrointestinal tract by
several mechanisms, including reduction of mucosal pros-
taglandin levels, reduction of mucosal blood flow, stimulat-
ing neutrophil activation, and possibly also stimulating
apoptosis.10 It is possible that several of these factors may
have been influenced by the NTs and further work is required
to understand this process. While it is possible that the
gastroprotective effects seen were mediated through topical
physicochemical actions, the results from our in vitro studies
suggested that protective mechanisms, such as stimulation of
restitution, may have been mediated through NT receptors.
Hundreds, if not thousands, of products are currently
marketed as ‘‘health food supplements’’.11 Seventy two per
cent of the American population use one or more health
supplement products regularly and 57% considered that these
therapies reduced their need for drugs and other medical
therapies. This results in an annual turnover of around
£1.4 billion ($2.4 billion) in the UK and £10 billion ($18 bil-
lion) in the USA, with about 8% annual growth.1 The sources
of these ‘‘natural’’ products are diverse and include bacteria
(for example, probiotics), plant (for example, prebiotics,
herbal remedies), animal (for example, colostrum), insect
(for example, honey), and marine (for example, sponges,
snails) origins. In relation to NTs for human use, these may
be obtained from bacterial cultures but also from human
placentas.7 A fuller review of the potential sources of
nutriceuticals is provided by Ghosh and Playford.1
Unfortunately, current evidence of the scientific validity of
most of these traditional and commercial compounds is
severely limited and the level of evidence used in support of
their claims often falls well below that acceptable in the
medical and scientific community.
The NTs investigated in this study are already marketed in
the USA as ‘‘over the counter’’ health food supplements and,
as with many of these products, the major marketing strategy
is via patient validatory statements. There have however been
some limited scientific studies; for example, an in vitro study
found that adenine NT stimulated the rate of wound healing
in monkey renal tubular epithelial cells.12 Similarly, an NT
mixture was effective when administered intravenously to
rats with D-galactosamine induced liver injury.13 In addition,
small pilot human studies have shown that polydeoxyriboNT,
given as eye drops, increased corneal epithelial regeneration14
and when given by combined intramuscular and subcuta-
neous route, increased the rate of healing of autologous skin
grafts.15
In conclusion, our studies have shown that NTs, commer-
cially available as over the counter ‘‘health food’’ supple-
ments for licensing purposes, possesses biological activity
when assessed using several models of gut integrity and
repair. They were able to induce the same biological repair
promoting responses as the potent ‘‘drug’’ epidermal growth
factor when tested under both in vitro (promigratory) and in
vivo (gastric damage) conditions (albeit at different concen-
trations). These results further emphasise that the division
between ‘‘food products’’ and ‘‘drugs’’, when considered in
terms of biological activity, is far from clear, and that these
products should be considered as ‘‘nutriceutical’’ or func-
tional foods. Similarly, the idea that natural products are
‘‘safe’’ whereas conventional drugs are ‘‘dangerous’’ is a gross
oversimplification. For example, although we have shown a
potentially useful effect in the current series of studies with
regard to oral administration of NTs and gastroprotection,
systemic administration actually caused exacerbation of the
degree of gastric injury. The reason(s) behind this difference
is unclear and deserves further investigation. Similarly, a
study in rats on the effect of dietary supplementation with a
nucleoside/NT mixture showed that it exacerbated the injury
associated with dextran sodium sulphate induced colitis.16
Further studies on the potential benefits (and risks) of NT
supplementation, therefore, appear justified.
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Answer
From question on page 164
The patient had dominant dorsal pancreatic duct syndrome
and intraductal papillary mucinous neoplasm (IPMN) in the
ventral pancreatic duct.
Figures 1 and 2 showed separated drainage of the common
bile duct and pancreatic duct into the duodenum. The
pancreatic duct could only be opacified by cannulation at
the minor papilla, not at the major papilla. We performed
endoscopic ultrasonography, which revealed echogenic
nodules within the dilated ventral pancreatic duct. She
received a modified Whipple operation with resection of the
pancreatic head, where the anatomical abnormalities were
located. Photography of the resected specimen (fig 3)
demonstrated a prominent dorsal pancreatic duct (DPD)
connecting to the minor papilla (mP). The ventral pancreatic
duct (VPD) manifested as a torturously septated duct without
grossly identifiable connection to the major papilla.
Microscopically, IPMN with borderline malignancy potential
was diagnosed over the ventral pancreatic duct (fig 4,
haematoxylin-eosin stain, original magnification 6100).
The postoperative course was uneventful and she has had
regular follow ups without recurrence of pancreatitis.
In this patient, mucin producing IPMN caused pancreatic
outflow obstruction and contributed to her recurrent attacks
of pancreatitis. Typically, IPMN is characterised by excess
mucus at the major papilla. The characteristic ‘‘fish mouth’’
appearance of the major papilla may be absent in the early
stages of IPMN, as is our case. Considering the synchronous
and metachronous malignancy potential in cases of IPMN,
close postoperative surveillance is mandatory for these
patients.
Figure 3 Photography of the dissected specimen of the pancreatic
head. VPD, ventral pancreatic duct; DPD, dorsal pancreatic duct; mP,
minor papilla.
Figure 4 Microscopic examination of the dilated ventral pancreatic
duct showing intraductal papillary mucinous neoplasm (haematoxylin-
eosin stain, original magnification6100).
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